Friday, April 29, 2016

BRIEF-Janssen's Imbruvica receives CHMP opinion for use in lymphocytic leukaemia patients

* Janssen's Imbruvica (ibrutinib) receives positive CHMP

opinion for expanded use in previously untreated chronic

lymphocytic leukaemia patients

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)